PT-141 (Bremelanotide) Research Guide: MC3R, MC4R & Melanocortin Signaling

PT-141 (Bremelanotide) Research Guide

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide examined as a melanocortin receptor agonist. Laboratory literature focuses on receptor binding, receptor selectivity, and downstream signaling, particularly at MC3R and MC4R. This page describes compound identity and pathway-level research only.

Compound identity and origin

PT-141 is structurally related to the melanocortin peptide family and was developed from work involving Melanotan II. The analog has a distinct receptor-activity profile, with laboratory studies commonly evaluating MC3R- and MC4R-associated responses and comparatively limited MC1R activity.

Melanocortin receptor profile

The melanocortin system includes five receptor subtypes, MC1R through MC5R. PT-141 research most often measures:

• MC3R: ligand binding and downstream signaling responses
• MC4R: receptor activation, selectivity, and central pathway measurements
• MC1R: comparative activity used to distinguish PT-141 from broader melanocortin analogs
• MC5R: secondary receptor-profile characterization where included in an assay panel

Results depend on assay design, cell model, concentration range, reference standard, and analytical method. Findings from one model should not be generalized beyond its stated conditions.

Structure and analytical identity

PT-141 is a cyclic seven-amino-acid analog. Its cyclic architecture and sequence are central to identity testing and receptor-interaction studies. Analytical characterization may include chromatographic purity, mass-based identity confirmation, and batch-specific documentation.

Research questions

Common laboratory questions include receptor-subtype selectivity, ligand-response relationships, concentration-dependent signaling, comparative activity against other melanocortin analogs, and material stability under controlled conditions.

Verification and documentation

The PT-141 10 mg vial listing references a Janoshik Analytical report dated June 2026. Researchers should match the identifier on received material to the public batch record rather than infer results across formats or lots.

Review the PT-141 (Bremelanotide) research material and current batch documentation for format, specifications, and availability.

Experimental limitations

Receptor-expression systems, assay endpoints, sample preparation, and handling conditions can materially affect measured responses. A receptor-binding result does not establish the same outcome in another model, and a report for vial material does not establish results for a separately formulated format.

Research-use statement

This material and the information on this page are intended only for controlled laboratory research. This page does not provide administration guidance.

Running the numbers for a protocol? Use the research calculators to convert mg, mL, and syringe units.